The Danish company’s controlling shareholder, the Novo Nordisk Foundation, had pushed him to step down after the share price ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

This transition reflects a planned and strategic evolution of MC2 Therapeutics, aligned with the company’s focus on commercial expansion.

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, is honored to share that it was awarded ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Sustainabilitycategory· 12:51 PM UTC Novo Nordisk's former chief makes comeback to steer choice of new CEO Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars ...

It is surprising that not even those who use the supercomputer are allowed to know its location. The CEO cites security ...

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the "Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and ...